Discovery research	Pre-clinical research	IND-enabling development	Clinical development	Indication (Mechanism of Action)
KY1005 - Anti-OX40L				Immune-mediated diseases
KY1044 - Anti-ICOS agonist				T-cell activation
KY1043 - PD-L1 Immunocytokine				Novel biology
KY1055 Anti-PD-L1xICOSbispecific mAb[2]				Novel bispecific biology
KY1003 - Anti-PD-L1				Checkpoint inhibition and depletion
KY1007 - Anti-CD7				Tumour-specific depletion
KY1041			MD Anderson Cancer Network™	T-cell activation
KY1051 - Anti-CXCR4			sosei HEPTARES	GPCR target
KY1062			sosei HEPTARES	GPCR target
KY1070 - Anti-BMP6				Anaemia of chronic inflammation
KY1009				Haematology/vascular
KY1049				Haemophilia (Novel bispecific)
KY1066				Iron-loading anaemia
KY1060				Infectious diseases (antibody)
KV7009				Infectious diseases (antibody)
Anti-pertussis toxin			BILL & MELINDA GATES foundation	Infectious diseases (antibody)
Anti-Malaria			BILL & MELINDA GATES foundation	Infectious diseases (antibody)
Malaria & HIV Vaccines			BILL & MELINDA GATES foundation	Infectious diseases (vaccines)